• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

  1. Ralph Naumann1,
  2. Astrid Vaic1,
  3. Bettina Beuthien-Baumann2,
  4. Jan Bredow2,
  5. Joachim Kropp2,
  6. Thomas Kittner3,
  7. Wolf-Gunter Franke2,
  8. Gerhard Ehninger1

Article first published online: 20 DEC 2001

DOI: 10.1046/j.1365-2141.2001.03147.x

Issue

British Journal of Haematology

British Journal of Haematology

Volume 115, Issue 4, pages 793–800, December 2001

Additional Information

How to Cite

Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J., Kittner, T., Franke, W.-G. and Ehninger, G. (2001), Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. British Journal of Haematology, 115: 793–800. doi: 10.1046/j.1365-2141.2001.03147.x

Author Information

  1. 1

    Department of Internal Medicine I,

  2. 2

    Department of Nuclear Medicine, PET Centre Rossendorf, and

  3. 3

    Department of Diagnostic Radiology, University Hospital Carl Gustav Carus at the Dresden University of Technology, Germany

* Dr. Ralph Naumann, Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus at the Dresden University of Technology, Fetscherstr. 74, D-01307 Dresden, Germany. E-mail: naumann@mk1.med.tu-dresden.de

Publication History

  1. Issue published online: 20 DEC 2001
  2. Article first published online: 20 DEC 2001
  3. Received 16 February 2001; accepted for publication 16 July 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (118K)

Keywords:

  • Hodgkin's disease;
  • non-Hodgkin's lymphoma;
  • 2-[F-18]fluoro-2-deoxy-D-glucose (FDG);
  • PET;
  • residual masses

The prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the assessment of post-treatment residual masses in patients with Hodgkin's disease (HD) or non-Hodgkin's lymphomas (NHL) was evaluated. We prospectively studied 58 patients with HD (n = 43) or NHL (n = 15) who had post-therapeutic complete remission with residual masses (CRu) indicated by computerized tomography. Analysis of 62 residual locations by FDG-PET was performed separately for HD and NHL. Patients with a PET-positive residual mass [standardized uptake value (SUV) > 3] had a recurrence rate of 62·5% (5/8 patients), whereas patients with PET-negative residual mass (SUV ≤ 3·0) showed a recurrence rate of 4% (2/50 patients, P = 0·004). A positive FDG-PET study correlated with a significantly poorer progression-free survival (P < 0·00001). No recurrence occurred in any of the 39 HD patients with a negative PET scan (negative predictive value, 100%). Four out of four NHL patients with a positive PET study relapsed (positive predictive value, 100%). In conclusion, FDG-PET is a suitable non-invasive method with a high degree of accuracy in the prediction of early recurrence in lymphoma patients with CRu.

View Full Article (HTML) Get PDF (118K)